GlassScriptPhysician profile
Claire J Lundgren
NPI 1043986276
$6,496.43
in general payments reported to CMS, 2019-2025
51 companies · $69.58 in 2025
The $69.58 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $2,466 · 2023: $2,931 · 2024: $858 · 2025: $69.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,466 · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,465.73 |
| Education | $392.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $673.92 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $571.09 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $415.72 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $370.26 | 2022-2024 | Imbruvica, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $319.91 | 2022-2024 | Opdivo, Opdualag |
| Eisai INC. | $308.81 | 2022-2024 | |
| Incyte Corporation | $282.74 | 2022-2023 | Monjuvi, Jakafi |
| Seagen INC. | $273.57 | 2022-2023 | Adcetris, Padcev |
| Astellas Pharma US INC | $272.98 | 2022-2023 | |
| Pfizer INC. | $209.41 | 2022-2024 | |
| Gilead Sciences, INC. | $206.46 | 2022-2023 | Trodelvy |
| Lilly USA, LLC | $205.79 | 2022-2024 | Jaypirca, Verzenio |
| Astrazeneca Pharmaceuticals LP | $194.81 | 2021-2024 | Imfinzi, Enhertu, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $179.02 | 2022 | |
| Acrotech Biopharma INC. | $172.64 | 2022-2023 | Beleodaq |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Lundgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.